Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment

Jing Li; Zuozhang Yang; Yi Li; Junfeng Xia; Dongqi Li; Huiling Li; Mingyan Ren; Yedan Liao; Shunling Yu; Yanjin Chen; Yihao Yang; Ya Zhang

doi:10.18632/oncotarget.8206

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment

Jing Li, Zuozhang Yang _, Yi Li, Junfeng Xia, Dongqi Li, Huiling Li, Mingyan Ren, Yedan Liao, Shunling Yu, Yanjin Chen, Yihao Yang and Ya Zhang

PDF | HTML | How to cite

Oncotarget. 2016; 7:44763-44778. https://doi.org/10.18632/oncotarget.8206

Metrics: PDF 3535 views | HTML 4829 views | ?

Abstract

Jing Li1,2,*, Zuozhang Yang1,*, Yi Li3,*, Junfeng Xia1,*, Dongqi Li1, Huiling Li1, Mingyan Ren1, Yedan Liao1, Shunling Yu1, Yanjin Chen1, Yihao Yang1 and Ya Zhang1

1 Bone and Soft Tissue Tumors Research Center of Yunnan Province, Department of Orthopaedics, the Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China

2 State Key Laboratory of Protein and Plant Gene Research, College of Life Sciences, Peking University, Beijing, China

3 Department of Oncology, Kunming General Hospital of Chengdu Military Command, Kunming, Yunnan, China

* These authors have contributed equally to this work

Correspondence to:

Zuozhang Yang, email:

Keywords: apoptosis, autophagy, necroptosis, chemotherapy resistance, osteosarcoma

Received: January 02, 2016 Accepted: March 07, 2016 Published: March 19, 2016

Abstract

Osteosarcoma is the most common primary bone tumor in children and adolescents. Although combined therapy including surgery and multi-agent chemotherapy have resulted in great improvements in the overall survival of patients, chemoresistance remains an obstacle for the treatment of osteosarcoma. Molecular targets or effective agents that are actively involved in cell death including apoptosis, autophagy and necroptosis have been studied. We summarized how these agents (novel compounds, miRNAs, or proteins) regulate apoptotic, autophagic and necroptotic pathways; and discussed the current knowledge on the role of these new agents in chemotherapy resistance in osteosarcoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8206

Publication Alerts

Reviews:

Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment

Abstract